Back to top
more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$86.72 USD

86.72
4,365,080

-0.64 (-0.73%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $86.73 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Zacks Industry Outlook Highlights: Sanofi, AstraZeneca, Novo Nordisk, Gilead Sciences and Valeant Pharmaceuticals International

Zacks Industry Outlook Highlights: Sanofi, AstraZeneca, Novo Nordisk, Gilead Sciences and Valeant Pharmaceuticals International

    Sweta Killa headshot

    Biotech ETF (BBH) Hits New 52-Week High

    This biotech ETF hit a new 52-week high. Are more gains in store for this ETF?

      Sarepta (SRPT) Q4 Loss Widens; Sales of Duchenne Drug Slow

      Sarepta Therapeutics, Inc. (SRPT) reported wider than expected loss in the fourth quarter of 2016.

        Arpita Dutt headshot

        Biotech Stock Roundup: Kite Soars on CAR-T Data, EXEL in Immuno-Oncology Deals

        Key updates this week include earnings results from companies like BioMarin and positive data on Kite's (KITE) lead pipeline candidate.

          Arpita Dutt headshot

          Pricing to Remain Pharma Headline Risk in 2017

          Drug pricing is an issue that has been weighing on pharma and biotech stocks for more than a year now.

            United Therapeutics (UTHR) Down on Q4 Earnings & Sales Miss

            United Therapeutics Corporation (UTHR) reported adjusted earnings of $2.64 per share for fourth-quarter 2016, which missed the Zacks Consensus Estimate of $3.62 by 27.1%.

              Arpita Dutt headshot

              Biotech Stock Roundup: Alexion Reports 4Q Results, Celgene MS Drug Looks Promising

              While Alexion (ALXN) reported a mixed quarter, Celgene provided promising data on a pipeline candidate.

                Zacks Investment Ideas feature highlights: Tesla, Volatility Index and Gilead

                Zacks Investment Ideas feature highlights: Tesla, Volatility Index and Gilead

                  David Bartosiak headshot

                  Five Major Myths about Options Trading

                  These are the five biggest myths about options trading

                    Falling Earnings Estimates Signal Weakness Ahead for Gilead Sciences (GILD)

                    Gilead Sciences (GILD) is one stock you should avoid as it has seen a significant price decline and negative earnings estimate revisions.

                      Arpita Dutt headshot

                      Biotech Stock Roundup: Regeneron's Praluent to Remain on Market for Now, GILD Presents HIV Data

                      Gilead (GILD) presented promising HIV data while Regeneron's PCSK9 inhibitor will remain on the market during the appeals process.

                        Gilead (GILD) Announces Data on Combination Therapy for HIV

                        Gilead Sciences, Inc. (GILD) recently announced positive data from a phase II study on HIV cocktail therapy.

                          The Zacks Analyst Blog Highlights: Gilead Sciences, Celgene, Fate Therapeutics, Exelixis and Akebia Therapeutics

                          The Zacks Analyst Blog Highlights: Gilead Sciences, Celgene, Fate Therapeutics, Exelixis and Akebia Therapeutics

                            Drug Stocks Earnings Slated for Feb 14: INCY, PRTA & More

                            The year 2017 seems to have started on a positive note for investors in the U.S. Approximately 71.6% of the companies (or 358 members) in the S&P 500 Index have reported results so far.

                              Arpita Dutt headshot

                              Forget Gilead, Buy These 5 Biotech Stocks Instead

                              With Gilead (GILD) providing a not-so-rosy outlook for 2017 as its HCV franchise continues to face challenges, here's a look at 5 biotech stocks that look better-positioned.

                                Sweta Killa headshot

                                Biotech ETFs Powered by Q4 Earnings

                                Improved earnings are driving the biotech space and ETFs higher over the past 10 days.

                                  Gilead (GILD) Beats Q4 Earnings & Sales, View Disappoints

                                  Gilead Sciences' (GILD) fourth quarter results beat on both earnings and sales but the guidance for 2017 was quite disappointing.

                                    Arpita Dutt headshot

                                    Biotech Stock Roundup: Amgen, Gilead Report 4Q Results, ARIAD Seeks EU Nod for Brigatinib

                                    Although both Amgen (AMGN) and Gilead reported better-than-expected 4Q results, the companies provided a disappointing sales outlook for 2017.

                                      Tracey Ryniec headshot

                                      Healthcare Stocks: The Buying Opportunity of the Year?

                                      Tracey and Kevin discuss whether healthcare stocks are still the ???sure things??? they???ve been the last 10 years.

                                        Madeleine Johnson headshot

                                        Gilead Sciences Posts Q4 Earnings Beat, Slumps on Weak Guidance

                                        Gilead Sciences Inc. (GILD) just released its fourth quarter fiscal 2016 financial results, posting earnings, before non-recurring items, of $2.64 cents per share and revenues of $7.3 billion

                                          Gilead Sciences (GILD) Q4 Earnings: What's in the Cards?

                                          Gilead Sciences Inc. (GILD ) is scheduled to report fourth-quarter 2016 results on Feb 7, after the market closes.

                                            Arpita Dutt headshot

                                            Key Takeaways from AbbVie's Q4 Call: Humira and the Pipeline

                                            2017 will be a year of significant R&D investment for AbbVie (ABBV) as well as several late-stage readouts which will give an insight into the company's long term growth prospects.

                                              Arpita Dutt headshot

                                              Biotech Stock Roundup: Synergy Drug Gets FDA Nod, AbbVie, GILD HCV Drugs under EU Review

                                              There were quite a few updates on the regulatory front this week in the biotech sector including FDA approval for Synergy's (SGYP) drug.

                                                Gilead (GILD) HCV Therapy Application Validated in Europe

                                                Gilead Sciences, Inc. (GILD) announced that its MAA for once-daily, single tablet regimen of Sovaldi, velpatasvir 100 mg and voxilaprevir 100 mg (SOF/VEL/VOX) for HCV treatment has been fully validated.

                                                  Is Gilead Sciences (GILD) a Great Stock for Value Investors?

                                                  Let's delve into the value metrics of Gilead Sciences (GILD) and determine whether it is a good value investment right now.